Skip to content
Open access

Computational identification of novel acetylcholinesterase inhibitors as potential treatments for Alzheimer's disease

Sep 2026 · Journal of Alzheimer's Disease · Vol 113, pp. 1917 - 1933 · 0 citations · 70 references
Medicine

TL;DR

Ligand code 24771824 stood out for establishing hydrophobic and aromatic interactions that maximize dispersive contributions and promote a rigid and stable conformation within the active site, consolidating it as the best candidate for future experimental validation.

Abstract

Background Alzheimer's disease represents a major public health issue that affects millions of people worldwide. Although symptomatic treatments are available, they neither prevent nor halt disease progression; therefore, it is necessary to develop new therapeutic alternatives. Objective To identify acetylcholinesterase inhibitors with potential biological activity through a computational protocol. Methods In this study, a computational approach based on virtual screening, molecular docking, and molecular dynamics simulations was applied to identify new potential acetylcholinesterase inhibitors. Results The results allowed the identification of three compounds with higher binding affinities than donepezil, which was used as a reference. Among them, ligand code 24771824 stood out for establishing hydrophobic and aromatic interactions that maximize dispersive contributions and promote a rigid and stable conformation within the active site. In contrast, ligand codes 151171 and 21081761 were favored by more directional polar contacts, which increased specificity but limited the overall affinity toward the enzyme. Conclusions Altogether, the free energy, structural fluctuation, hydrogen bond occupancy, and molecular clustering analyses suggest that 24771824 exhibits the most favorable energetic and dynamic behavior, consolidating it as the best candidate for future experimental validation.

Read PDF

Similar papers

Sep 2026

Computational discovery and dynamic profiling of dual acetylcholinesterase and monoacylglycerol lipase inhibitors for Alzheimer's disease.

Compound H34 is highlighted as a promising dual-target candidate for Alzheimer's disease therapy and illustrates the effectiveness of integrated computational strategies in early-stage drug discovery.

The-Huan Tran, Thai-Son Tran, Thanh-Dao Tran · 0 citations
Open access Aug 2026

Multiscale mechanistic modeling for the rational design of novel dual-target candidates against acetylcholinesterase and NADPH oxidase: an advanced computational study

New derivatives based on benzofuran and pyrazole scaffolds designed and assessed for their antioxidant potential and acetylcholinesterase inhibitory activity provide further evidence for the potential of the designed compounds to behave as multi-target ligands with AChE inhibition and antioxidant properties that would...

Mohamed El Fadili, M. Er-rajy, S. Mujwar et al. · 0 citations
Open access Aug 2026

Structure-based Design and Computational Evaluation of Spiropyrrolidine Derivatives as Novel Acetylcholinesterase Inhibitors for Alzheimer’s Disease

Several synthesized spiropyrrolidine compounds exhibited favorable binding interactions with key active site residues and showed promising drug-like properties, which may serve as potential leads for the development of novel AChE inhibitors and may provide new insights for therapeutic strategies in Alzheimer's disease.

Paranthaman Shamala, Mohamed Noor Shaik, P. B. et al. · 0 citations
Review Sep 2026

Cholinesterase Inhibitors in Alzheimer's Disease: Medicinal Chemistry, Mechanistic Insights, and Emerging Multitarget Strategies.

The need for rational drug design to develop multitargetdirected drugs that may have disease-modifying effects, to overcome the limitations of existing symptomatic cholinesterase-inhibitor monotherapy is underscored.

Anuradha Mehra, Rahul Sharma, Amit Mittal · 0 citations
Open access Sep 2026

Novel Pyrazoline Derivatives as Therapeutic Candidate for Alzheimer’s Disease: An Integrated Network Pharmacology and 3D-QSAR Modelling

Findings highlight APOE, BACE1, and CSF1R as key therapeutic targets as key therapeutic targets and identify compound 2a as a promising multi-target lead candidate for additional experimental validation in AD.

Md. Mainuddin Hossain, Towfika Rahman Singdha, Saiful Islam Sakib et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.